Kenvue Inc. (NYSE:KVUE) to Issue Quarterly Dividend of $0.21

Kenvue Inc. (NYSE:KVUE - Get Free Report) declared a quarterly dividend on Wednesday, April 16th, RTT News reports. Investors of record on Wednesday, May 14th will be given a dividend of 0.205 per share on Wednesday, May 28th. This represents a $0.82 annualized dividend and a yield of 3.69%. The ex-dividend date is Wednesday, May 14th.

Kenvue has a dividend payout ratio of 66.7% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kenvue to earn $1.24 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 66.1%.

Kenvue Price Performance

Shares of NYSE KVUE traded down $1.15 during midday trading on Monday, reaching $22.24. 6,592,867 shares of the company traded hands, compared to its average volume of 17,048,896. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market cap of $42.67 billion, a PE ratio of 41.96, a PEG ratio of 2.62 and a beta of 1.02. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The stock's 50-day simple moving average is $22.91 and its 200-day simple moving average is $22.41.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

KVUE has been the topic of several recent research reports. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Finally, UBS Group decreased their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.